Protagenic Therapeutics (NASDAQ: PTIX) stock and warrants removed from Nasdaq listing

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. is having its common stock and warrants removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 under Section 12(b) of the Securities Exchange Act of 1934, certifying that it has followed its own rules and the SEC’s requirements to strike these securities from listing and withdraw their registration on the exchange. The filing lists Protagenic’s principal executive offices in New York and identifies the affected securities as its common stock and warrants.

Positive

• None.

Negative

• Protagenic Therapeutics’ common stock and warrants are being removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act.

Insights

Equity markets and listing specialist

Nasdaq is removing Protagenic’s common stock and warrants from its exchange, ending their Nasdaq listing.

The filing shows Nasdaq Stock Market LLC submitting a Form 25 to remove Protagenic Therapeutics, Inc. common stock and warrants from listing and registration under Section 12(b) of the Exchange Act. The document states that Nasdaq has complied with its rules to strike the class of securities from listing and withdraw registration.

This action typically means the securities will no longer trade on Nasdaq and may move to a less liquid trading venue, which can affect visibility and trading dynamics. The text also notes that the issuer has complied with exchange rules and SEC requirements governing voluntary withdrawal, indicating that both the exchange’s and the issuer’s procedural steps are in place.

For investors, the key consequence is the loss of a major-exchange listing for Protagenic’s common stock and warrants, which can influence trading access and perception of the company. Subsequent company communications and future filings may provide more detail on post-delisting trading arrangements.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-12555

Issuer:	Protagenic Therapeutics, Inc.\new
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	149 Fifth Ave
	Suite 500
	New York	NEW YORK	10010
Telephone number:					213-260-4342

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock, Warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-01-23	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nasdaq file regarding Protagenic Therapeutics (PTIX)?

Nasdaq Stock Market LLC filed a Form 25 to remove Protagenic Therapeutics, Inc. common stock and warrants from listing and registration under Section 12(b) of the Exchange Act.

Which Protagenic Therapeutics (PTIX) securities are affected by this Form 25?

The filing covers Protagenic Therapeutics, Inc. common stock and warrants, which are being struck from listing and registration on the Nasdaq Stock Market LLC.

Is the Protagenic Therapeutics (PTIX) delisting described as compliant with rules?

Yes. The document states that Nasdaq has complied with its rules to strike the class of securities from listing and registration, and that the issuer has complied with the exchange’s rules and SEC requirements for voluntary withdrawal.

Who signed the Protagenic Therapeutics (PTIX) Form 25 for Nasdaq?

The notification is signed on behalf of Nasdaq Stock Market LLC by Aravind Menon, identified as a Hearings Advisor.

Under which law is Protagenic Therapeutics (PTIX) being removed from Nasdaq listing?

The removal is made under Section 12(b) of the Securities Exchange Act of 1934, with citations to 17 CFR 240.12d2-2 provisions governing delisting and withdrawal of registration.

Where is Protagenic Therapeutics, Inc. headquartered according to the Form 25?

The filing lists Protagenic Therapeutics, Inc.’s principal executive offices at 149 Fifth Ave, Suite 500, New York, NY 10010, with telephone number 213-260-4342.